Please ensure Javascript is enabled for purposes of website accessibility
ホーム > 製品 > 抗体 > 1次抗体

Anti-Human LAG-3 Recombinant Nanobody (SAA2195) (HB613013)

Anti-Human LAG-3 Recombinant Nanobody (SAA2195)
Anti-Human LAG-3 Recombinant Nanobody (SAA2195)
価格(USD):
スペック:
  • 20ug
  • 50ug
  • 100ug
  • 1mg
数量:
お問い合わせ
  • 概要

  • イメージ

  • 参考文献

  • データシート

  • SDS

概要
カタログ番号HB613013
説明
Anti-Human LAG3 Nanobody (SAA2195) [SAA2195] (HB613013) is a alpaca monoclonal antibody detecting LAG3 in ELISA. Suitable for Human.
種反応性Human
アプリケーションELISA
宿主種Alpaca
クローン性Monoclonal
アイソタイプVHH-8His-Cys-tag
クローンIDSAA2195
ターゲット CD223, FDC, LAG-3, LAG3, Lymphocyte activation gene 3 protein, Secreted lymphocyte activation gene 3 protein, sLAG-3
エンドトキシンレベル < 10 EU/mg
純度 >95% as determined by SDS-PAGE.
精製 Protein A/G purified from cell culture supernatant.
アクセッション番号 P18627
形態 Liquid
保存バッファー 0.01M PBS pH 7.4.

データシートのハードコピーまたはロット固有のCOAに記載された具体的なバッファー情報を参照してください。

製品使用情報
アプリケーション 希釈
ELISA 1:2000-1:20000
安定性と保存 Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
背景

Lymphocyte activation gene 3 protein (CD223/LAG3) is a ~57 kDa protein. Inhibitory receptor on antigen activated T-cells. Delivers inhibitory signals upon binding to ligands, such as MHC class II, its main ligand present at the surface of antigen-presenting cells (APCs), and FGL1, which is secreted by hepatocytes and certain types of tumor cells. Ligand-binding initiates a signaling that inhibits the T-cell receptor (TCR) in the immunological synapse, preventing T-cell activation. Mechanistically, ligand-binding promotes (1) ubiquitination of the KIEELE motif, unleashing the RRFSALE motif from the membrane and (2) leading to the formation of condensates with the TCR component CD3E, thereby disrupting the association between CD3E and LCK and preventing TCR activation. May inhibit antigen-specific T-cell activation in synergy with PDCD1/PD-1. CD223 is the therapeutic target of relatlimab (Opdualag).

1. Camisaschi, C. et al. (2010) Journal of immunology (Baltimore, Md. : 1950) 184, 6545-51. PMID: 20421648
2. Ming, Q. et al. (2022) Nature immunology 23, 1031-1041. PMID: 35761082
3. Huard, B. et al. (1994) European journal of immunology 24, 3216-21. PMID: 7805750
4. Huard, B. et al. (1996) European journal of immunology 26, 1180-6. PMID: 8647185
5. Wang, J. et al. (2019) Cell 176, 334-347.e12. PMID: 30580966
6. MacLachlan, BJ. et al. (2021) European journal of immunology 51, 331-341. PMID: 32920841
7. Petersen, J. et al. (2024) Science immunology 9, eads5122. PMID: 39671469
8. Huard, B. et al. (1995) European journal of immunology 25, 2718-21. PMID: 7589152
10. Jiang, Y. et al. (2025) Cell 188, 2354-2371.e18. PMID: 40101708
注意事項 For research use only.
イメージ
  • Anti-Human LAG-3 Recombinant Nanobody (SAA2195)

    SDS-PAGE

    SDS-PAGE for Anti-Human LAG3 Nanobody (SAA2195)

参考文献
Formula
Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)
Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.
Mass
=
Concentration
×
Volume
Molecular Weight *
g/mol
Formula
C₁ × V₁ = C₂ × V₂
Enter any 3 of the 4 values to solve for the unknown.
Stock Solution
C₁ (Stock Conc.)
×
V₁ (Stock Vol.)
=
Working Solution
C₂ (Working Conc.)
×
V₂ (Working Vol.)
レコメンデーション

お問い合わせ カスタムクォート、大量リクエストおよびその他の問題については

メール: [email protected]

ディストリビューターリスト